Scimega Research has been selected by the Quebec – Clinical Research Organization in Cancer (Q-CROC) to oversee the conduct of three studies to identify predictive biomarkers in drug-resistant tumors.
In February 2013, the Minister of Finance and the Economy, and the Minister for Industrial Policy, and the Quebec Economic Development Bank, Élaine Zakaïb, invested $10 million in the Personalized Medicine Partnership for Cancer (PMPC), a public-private partnership for implementation of personalized medicine in cancer. The PMPC will be supported by the Q-CROC’s hospital and university network, which currently has members in 15 healthcare establishments and 16 research centers in the province.
“Personalized medicine represents a paradigm shift for the key stakeholders involved in cancer drug development. Collectively, we all have an important role to play in the fight against cancer and this is an excellent example of a unifying partnership that brings us one step closer to making personalized medicine a reality, and patient-centered treatment, a standard,” said Denise Deakin, president and co-founder of Scimega Research.
Scimega, Q-CROC in Biomarkers Research Alliance
By Kristin Brooks
Published December 12, 2013
blog comments powered by Disqus